COVID-19 in Fabry disease: a reference center prospective study.
Coronavirus disease 2019 (COVID-19)
Fabry disease
SARS-CoV-2 Antibody Titer
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
28 06 2022
28 06 2022
Historique:
received:
21
02
2022
accepted:
06
06
2022
entrez:
28
6
2022
pubmed:
29
6
2022
medline:
1
7
2022
Statut:
epublish
Résumé
During the coronavirus disease-19 (COVID-19) pandemic, vulnerable populations must be identified to prevent increased mortality. Fabry disease (FD) is a rare X-linked lysosomal storage disorder leading to chronic kidney disease (CKD), cardiomyopathy, pneumonopathy and premature strokes. Little is known whether SARS-CoV-2 infection bears a particular risk for FD patients. During pandemic (02.2020-03.2021) we have regularly followed 104 unvaccinated FD patients. In 61/104, titre of serum antibodies against SARS-CoV-2 were measured and SARS-CoV-2 PCR test was performed in symptomatic patients or in case of positivity of other family members. The symptoms and duration of COVID-19 were reported by the patients or the treating physician. No deaths or intensive care unit hospitalizations occurred. 13/104 (12.5%) were diagnosed with SARS-CoV-2 infection (16.7% (4/24) men 12.2% (6/49) women of classic phenotype, 25% (3/12) of the men and 0% (0/8) of the women of later- onset phenotype). Of those, 2/13 (15.4%) patients-both kidney transplant recipients-developed severe COVID-19, were hospitalized, and required a high-flow oxygen mask. The rest either developed mild COVID-19 manifestations (8/13, 61.5%) or were asymptomatic (3/13, 23.1%). 2/13 (15.4%) of the patients experienced Fabry pain crisis and 3/13 (23.1%) long COVID-19 like symptoms. Similar to the general population, in FD patients the risk for severe COVID-19 seems to be driven by the immune system rather than by FD itself. Immunosuppression in kidney transplant recipients represented the highest risk in this population.
Sections du résumé
BACKGROUND
During the coronavirus disease-19 (COVID-19) pandemic, vulnerable populations must be identified to prevent increased mortality. Fabry disease (FD) is a rare X-linked lysosomal storage disorder leading to chronic kidney disease (CKD), cardiomyopathy, pneumonopathy and premature strokes. Little is known whether SARS-CoV-2 infection bears a particular risk for FD patients.
METHODS
During pandemic (02.2020-03.2021) we have regularly followed 104 unvaccinated FD patients. In 61/104, titre of serum antibodies against SARS-CoV-2 were measured and SARS-CoV-2 PCR test was performed in symptomatic patients or in case of positivity of other family members. The symptoms and duration of COVID-19 were reported by the patients or the treating physician.
RESULTS
No deaths or intensive care unit hospitalizations occurred. 13/104 (12.5%) were diagnosed with SARS-CoV-2 infection (16.7% (4/24) men 12.2% (6/49) women of classic phenotype, 25% (3/12) of the men and 0% (0/8) of the women of later- onset phenotype). Of those, 2/13 (15.4%) patients-both kidney transplant recipients-developed severe COVID-19, were hospitalized, and required a high-flow oxygen mask. The rest either developed mild COVID-19 manifestations (8/13, 61.5%) or were asymptomatic (3/13, 23.1%). 2/13 (15.4%) of the patients experienced Fabry pain crisis and 3/13 (23.1%) long COVID-19 like symptoms.
CONCLUSIONS
Similar to the general population, in FD patients the risk for severe COVID-19 seems to be driven by the immune system rather than by FD itself. Immunosuppression in kidney transplant recipients represented the highest risk in this population.
Identifiants
pubmed: 35765080
doi: 10.1186/s13023-022-02386-7
pii: 10.1186/s13023-022-02386-7
pmc: PMC9237963
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
250Informations de copyright
© 2022. The Author(s).
Références
Mol Genet Metab. 2018 Jul;124(3):189-203
pubmed: 30017653
Mol Genet Metab. 2020 Sep - Oct;131(1-2):124-125
pubmed: 32741663
PLoS One. 2017 Jul 25;12(7):e0180437
pubmed: 28742806
Nat Rev Nephrol. 2021 Jan;17(1):46-64
pubmed: 33077917
Nat Rev Immunol. 2020 Apr;20(4):229-238
pubmed: 31836872
ESC Heart Fail. 2020 Jun;7(3):825-834
pubmed: 32100468
Genet Med. 2009 Nov;11(11):790-6
pubmed: 19745746
Jpn J Infect Dis. 2021 May 24;74(3):228-232
pubmed: 33250492
Med Hypotheses. 2020 Nov;144:110282
pubmed: 33254586
Appl Clin Genet. 2019 Mar 05;12:35-50
pubmed: 30881085
J Inherit Metab Dis. 2020 Mar;43(2):326-333
pubmed: 31449323
Eur J Clin Invest. 2004 Mar;34(3):236-42
pubmed: 15025684
Lancet. 2021 Oct 23;398(10310):1482-1484
pubmed: 34619100
Clin Kidney J. 2020 Dec 24;13(6):913-925
pubmed: 33391734
Cell. 2020 Dec 10;183(6):1520-1535.e14
pubmed: 33157038
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
Mol Genet Metab. 2021 Apr;132(4):234-243
pubmed: 33642210
Lancet Respir Med. 2021 Feb;9(2):129
pubmed: 33453162
BMJ Open Respir Res. 2018 Apr 21;5(1):e000277
pubmed: 29713479
J Am Soc Nephrol. 2017 May;28(5):1631-1641
pubmed: 27979989
Mol Genet Metab. 2020 Jul;130(3):170-171
pubmed: 32386848
J Basic Microbiol. 2021 Mar;61(3):180-202
pubmed: 33460172
Am J Transplant. 2021 Aug;21(8):2919-2921
pubmed: 34058052
Mol Genet Metab. 2018 Feb;123(2):148-153
pubmed: 28728877
Mol Genet Metab Rep. 2021 Dec;29:100802
pubmed: 34545322
Postgrad Med J. 2021 May;97(1147):312-320
pubmed: 32978337
Mol Genet Metab Rep. 2019 Feb 06;19:100454
pubmed: 30775256
J Am Soc Nephrol. 2021 Sep;32(9):2153-2158
pubmed: 34135083
Am J Respir Crit Care Med. 1997 Mar;155(3):1004-10
pubmed: 9116979